The news of the accelerated approval of Biogen's Alzheimer's disease drug aducanumab by the FDA has attracted widespread attention in the industry. The cheers said that this is the first new drug approved by the FDA for the treatment of AD since 2003. It is gratifying for the FDA to stand out from the crowd; there are also views that the FDA's approval is actually "drinking poison to quench thirst", regardless of the opposition of the external expert group. Because of the wrong choice, many experts who participated in the review directly resigned. At the same time, there are also views that "hope is more important than curative effect". Drugs carry not only scientific attributes, but also the mission of delivering hope to patients and their families.